NHSA Guangzhou Drug-List Conference Releases 2025 Medical Insurance Formulary
The National Healthcare Security Administration (NHSA) announced it will host the 2025 Innovative Drugs High-Quality...
Nationally negotiated drugs
NHSA 2025 Drug Catalog Review: 6 Drugs Rejected, 718 Applications Reviewed
The National Healthcare Security Administration (NHSA) on Aug. 28, 2025 announced the formal review outcomes...
NHSA Finalizes 2025 Drug Catalog Adjustment Plan with Minimal Changes from Draft
The National Healthcare Security Administration (NHSA) this week issued the finalized “2025 National Basic Medical...
NHSA Unveils Plans for 2025 National Drug List Adjustments and Commercial Insurance Drug List
This week, China’s National Healthcare Security Administration (NHSA) released two draft documents detailing a plan...
NHSA Revises 2024 NRDL Drug Information Based on Public Feedback
China’s National Healthcare Security Administration (NHSA) has announced revisions to the information about certain drugs...
NHSA to Announce NRDL Adjustment Results at November 28th Press Conference
The National Healthcare Security Administration (NHSA) will unveil the results of the negotiation and price...
National Reimbursement Drug List (NRDL) Negotiations Conclude with Lower Generic Drug Approval Rate
The National Reimbursement Drug List (NRDL) negotiations for the year have concluded, with less than...
Jiangxi Province to Implement Direct Medical Insurance Fund Payments for NRDL Drugs from December 2024
The Jiangxi Province Healthcare Security Administration and the Jiangxi Provincial Department of Finance have jointly...
China’s NHSA Sets October Dates for National Reimbursement Drug List Negotiations and Price Bidding
The National Healthcare Security Administration (NHSA) has announced that the one-site negotiation and price bidding...
NHSA Preliminary Review Identifies Potential NRDL Additions, Including Novel Therapies and ADCs
The National Healthcare Security Administration (NHSA) has released a preliminary list of drugs that have...
NHSA Seeks Public Input on National Reimbursement Drug List Adjustments
The National Healthcare Security Administration (NHSA) has unveiled the adjustment plan for the National Reimbursement...
Jiangsu Province Announces Dual Channel Management and Separate Payment Drug List
Jiangsu province’s healthcare security administration has released a list identifying drugs subject to dual channel...
Hunan Province Releases “Dual Channel” Drug Payment List with 226 Products
The Hunan Healthcare Security Administration has published a list of 226 drugs to be included...
China’s 2023 NRDL Expands Coverage with 126 New Drugs, Aims for Savings and Accessibility
The National Healthcare Security Administration (NHSA) has released the finalized National Reimbursement Drug List (NRDL)...
National Reimbursement Drug List Negotiations and Bidding Process Conclude
The on-site negotiation and bidding processes for the 2023 update to China’s National Reimbursement Drug...
NHSA Completes Expert Review for National Reimbursement Drug List Updates
The National Healthcare Security Administration (NHSA) has announced the completion of the expert review stage...
Beijing Insurance Bureau Launches Pilot to Boost Access to NRDL Drugs
The Beijing Municipal Medical Insurance Bureau has announced the initiation of pilot work aimed at...
NHSA Clears Retagliptin and Ambroxol for National Reimbursement Drug List Inclusion
The National Healthcare Security Administration (NHSA) has completed a review of the National Reimbursement Drug...
NHSA Releases Preliminary Review Results for National Reimbursement Drug List Adjustments
The National Healthcare Security Administration (NHSA) has released a notification disclosing the drugs that have...
NHSA Unveils Updated National Reimbursement Drug List Rules for 2023
The National Healthcare Security Administration (NHSA) has released the updated rules that will govern this...